Skip to content
Medical Health Aged Care

2024 Federal Budget should fund GP-led living guidelines to make Australia healthier

Royal Australian College of GPs 2 mins read

The Royal Australian College of GPs (RACGP) is calling on the Federal Government to invest in ‘living’ guidelines for preventive care so patient care can be informed by the latest evidence and improve health outcomes.

With health research and evidence changing rapidly, Australia’s largest peak GP body is calling for funding to turn existing GP clinical guidelines into ‘living guidelines’ in its pre-Budget submission 2024-25.

Clinical guidelines provide evidence-backed recommendations for medical professionals and patients to inform health decisions, weighing benefits, potential harms, and the certainty of evidence.

While most guidelines are updated at specific intervals such as every three years, living guidelines incorporate relevant new evidence as it becomes available to allow clinicians to stay up to date with the latest research, but require continual surveillance and review.

A nationwide newsGP poll identified GPs find it most challenging to stay across rapidly changing evidence on:

  • COVID-19 – 24%
  • Smoking/vaping cessation – 20%
  • PSA testing – 14%
  • Preventive health – 14%
  • MS-2 Step – 6%.

RACGP President Dr Nicole Higgins said living guidelines would make a significant difference for GPs and their patients.

“Health research and evidence changes so rapidly that guidelines quickly become outdated, and GPs need to spend a lot of time looking at new research to keep up to date,” she said.

“Funding for GP led living guidelines will mean Australians can get the latest evidence-based care – this will make Australia healthier and reduce costs to the health system.

“We are calling for funding for preventive care guidelines which would have a significant impact on health outcomes. The leading causes of death and disability in Australia are preventable or can be delayed with early intervention through general practice.

“For too long, Australian governments have underinvested in preventive care – currently just 2% of our total health spending goes to prevention. The National Preventive Health Strategy calls for it to increase to 5% by 2030.

“Funding preventive care is the most cost-effective health investment. The Productivity Commission estimated that improving the health of people in poor or fair health would result in an extra $4 billion GDP growth annually in 2017 – it’s likely a lot more now, given the increasing burden of chronic disease in Australia.

“I strongly encourage the government to make this investment in RACGP guidelines in the next Budget. It will help all Australians get the latest evidence-based care, improve our health, and reduce pressure on our hospitals.”

~ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992[email protected]

Follow us on Twitter: @RACGP and Facebook.

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 13/01/2026
  • 14:06
Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney

Simple tool predicts who is most at risk of dementia after stroke

A new international study led by researchers from UNSW Sydney’s Centre for Healthy Brain Ageing (CHeBA) has developed the first practical, five-year dementia risk…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 13/01/2026
  • 10:50
Nova Eye Medical (ASX:EYE)

Nova Eye Medical Reports Record Sales Result for December 2025 Quarter

HIGHLIGHTS Record December quarter with global sales of US$6.1 million, up 38% on pcp and 25% on the September 2025 quarter Global six-month sales…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 13/01/2026
  • 10:09
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Reports Clinical Response for StemSmart(TM) Treatment in Fistulising Crohn’s Disease Under Special Access Program

13 January 2026 – Perth, Australia | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has today announced a “Clinical Response” from patients treated with its patented StemSmart™ Mesenchymal Stem Cell (MSC) therapy under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS) for fistulising Crohn’s disease. Three of four patients treated in Cohort 1 of the Special Access Program demonstrated a successful “Clinical Response” following treatment with StemSmart™, with the fourth patient showing a partial response with further clinical assessment needed. A Clinical Response is defined as either closure of at least 50 per cent of fistula openings or a reduction in fistula…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.